Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 6:20 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 194 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: CD Clear all
Active, not recruiting Phase 1 Interventional

Study of Tagraxofusp for Post-Transplant Maintenance for Patients With CD 123+ AML, MDS, MF and CMML (HSCT 002)

NCT05233618
View directory record Official record
Conditions
Myelofibrosis, Chronic Myelomonocytic Leukemia, Acute Myeloid Leukemia
Interventions
Tagraxofusp
Drug
Lead sponsor
Karen Ballen, MD
Other
Eligibility
18 Years to 75 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 20, 2026, 6:20 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Vedolizumab Subcutaneous (SC) as Maintenance Therapy in Crohn's Disease (CD)

NCT02611817
View directory record Official record
Conditions
Crohn's Disease
Interventions
Vedolizumab SC 108 mg, Placebo, Vedolizumab IV 300 mg
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 80 Years
Enrollment
644 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
30
States / cities
Phoenix, Arizona • Hamden, Connecticut • Middletown, Connecticut + 27 more
Source: ClinicalTrials.gov public record
Updated May 25, 2022 · Synced Oct 20, 2026, 6:20 PM EDT
Recruiting No phase listed Observational

COMPARE - Pediatric Inflammatory Bowel Disease (PIBD)

NCT07198113
View directory record Official record
Conditions
Ulcerative Colitis, Pediatric, Inflammatory Bowel Diseases, Crohn Disease
Interventions
Not listed
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
1 Year to 18 Years
Enrollment
1,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
4
States / cities
Chapel Hill, North Carolina • Charlotte, North Carolina • Durham, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2026 · Synced Oct 20, 2026, 6:20 PM EDT
Active, not recruiting Phase 3 Interventional

Efficacy, Safety and Tolerability Study of ND0612 vs. Oral Immediate Release Levodopa/Carbidopa (IR-LD/CD) in Subjects With Parkinson's Disease Experiencing Motor Fluctuations

NCT04006210
View directory record Official record
Conditions
Parkinson's Disease
Interventions
ND0612 Solution for SC infusion, Placebo for SC infusion, Oral IR-LD/CD, Placebo for Oral IR-LD/CD
Combination Product · Drug
Lead sponsor
NeuroDerm Ltd.
Industry
Eligibility
30 Years and older
Enrollment
381 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
38
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 34 more
Source: ClinicalTrials.gov public record
Updated May 21, 2025 · Synced Oct 20, 2026, 6:20 PM EDT
Not listed No phase listed Observational

Microbial and Human Determinants of the Onset of IBD Flares

NCT05463900
View directory record Official record
Conditions
Ulcerative Colitis, Crohn Disease, Irritable Bowel, Crohns Disease Aggravated, Crohn Disease in Remission
Interventions
Not listed
Lead sponsor
Viome
Industry
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Bothell, Washington
Source: ClinicalTrials.gov public record
Updated Oct 30, 2023 · Synced Oct 20, 2026, 6:20 PM EDT
Terminated Not applicable Interventional

Blood and Stool Molecular Biomarkers Longitudinal Detection Study in Crohn's Disease (CD) Patients

NCT03566407
View directory record Official record
Conditions
Crohn's Disease
Interventions
Colonoscopy
Procedure
Lead sponsor
Prometheus Laboratories
Industry
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
5
States / cities
Los Angeles, California • Ventura, California • Hamden, Connecticut + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2019 · Synced Oct 20, 2026, 6:20 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Levels of the Stat4 Alpha and Stat4 Beta Isoforms in PBMCs From Patients With Crohn's Disease and Ulcerative Colitis

NCT00586599
View directory record Official record
Conditions
Inflammatory Bowel Disease, Crohn's Disease, Ulcerative Colitis
Interventions
measurement of inflammatory markers
Other
Lead sponsor
Indiana University
Other
Eligibility
7 Years to 17 Years
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2014
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Apr 3, 2015 · Synced Oct 20, 2026, 6:20 PM EDT
Enrolling by invitation Phase 4 Interventional

INSIGHT-IBD Pragmatic Study

NCT07686757
View directory record Official record
Conditions
Ulcerative Colitis (UC), Crohn Disease (CD)
Interventions
Mirikizumab, Anti-TNF agents, anti-integrin antibodies, IL-12, IL-23
Drug
Lead sponsor
Specialty Networks Research.
Network
Eligibility
21 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
11
States / cities
Sun City, Arizona • Glenview, Illinois • Gurnee, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 20, 2026, 6:20 PM EDT
Completed Phase 2 Interventional Results available

Lenalidomide, Rituximab, Cyclophosphamide, and Dexamethasone in Treating Patients With Previously Untreated Low-Grade Non-Hodgkin Lymphoma

NCT00784927
View directory record Official record
Conditions
Lymphoma
Interventions
rituximab, cyclophosphamide, dexamethasone, lenalidomide
Biological · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 120 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
2
States / cities
Scottsdale, Arizona • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 7, 2016 · Synced Oct 20, 2026, 6:20 PM EDT
Terminated Phase 3 Interventional Results available

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

NCT01190839
View directory record Official record
Conditions
Crohn's Disease
Interventions
Infliximab, Placebo
Biological · Drug
Lead sponsor
Janssen Biotech, Inc.
Industry
Eligibility
18 Years to 99 Years
Enrollment
297 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
62
States / cities
Birmingham, Alabama • La Jolla, California • Orange, California + 59 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2016 · Synced Oct 20, 2026, 6:20 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

A Study of Immune System Activity in Healthy Adults

NCT00014053
View directory record Official record
Conditions
HIV Infections, HIV Seronegativity
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
U.S. locations
9
States / cities
San Francisco, California • Denver, Colorado • Honolulu, Hawaii + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2008 · Synced Oct 20, 2026, 6:20 PM EDT
Completed Phase 1 Interventional

CD-NP (Cenderitide) Therapy for the Preservation of Left Ventricular Function

NCT02071602
View directory record Official record
Conditions
ST Elevation (STEMI) Myocardial Infarction of Anterior Wall
Interventions
CD-NP
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 10, 2021 · Synced Oct 20, 2026, 6:20 PM EDT
Completed Phase 3 Interventional

rhBMP-2/CRM/CD HORIZON® Spinal System Pivotal Study

NCT00707265
View directory record Official record
Conditions
Degenerative Disc Disease
Interventions
rhBMP-2/CRM/CD HORIZON® Spinal System, Autograft/CD HORIZON® Spinal System
Device
Lead sponsor
Medtronic Spinal and Biologics
Industry
Eligibility
18 Years and older
Enrollment
463 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2010
U.S. locations
28
States / cities
Phoenix, Arizona • Orange, California • Santa Monica, California + 25 more
Source: ClinicalTrials.gov public record
Updated May 10, 2023 · Synced Oct 20, 2026, 6:20 PM EDT
Completed No phase listed Observational

Precision Opioid Care After Cesarean Delivery (PRECISE-CD)

NCT05280743
View directory record Official record
Conditions
Cesarean Section Complications, Opioid Use
Interventions
Oxycodone
Drug
Lead sponsor
Grace Lim, MD, MS
Other
Eligibility
18 Years and older · Female only
Enrollment
341 participants
Timeline
2022 – 2024
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 5, 2024 · Synced Oct 20, 2026, 6:20 PM EDT
Completed Not applicable Interventional

Supplementation of Vitamin D3 in Patients With Inflammatory Bowel Diseases and Hypovitaminosis D

NCT01877577
View directory record Official record
Conditions
Crohn's Disease (CD), Ulcerative Colitis (UC)
Interventions
Vitamin D3
Dietary Supplement
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Fresno, California
Source: ClinicalTrials.gov public record
Updated Jul 2, 2014 · Synced Oct 20, 2026, 6:20 PM EDT
Recruiting Not applicable Interventional

Ultrasound-Guided Versus Standard Margin Selection in Ileocecal Resection of Terminal Ileal CD

NCT07680283
View directory record Official record
Conditions
Crohn's Disease (CD)
Interventions
IOUS-guided margin selection
Device
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 20, 2026, 6:20 PM EDT
Not listed Phase 3 Interventional

A Study of AP-CD/LD in Fluctuating Parkinson's Disease Patients Who Completed IN 11 004

NCT02615873
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Accordion Pill™ Carbidopa/Levodopa
Drug
Lead sponsor
Intec Pharma Ltd.
Industry
Eligibility
30 Years to 100 Years
Enrollment
460 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
37
States / cities
Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 33 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2018 · Synced Oct 20, 2026, 6:20 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Study to Investigate the Safety of OpCT-001 in Adults Who Have Primary Photoreceptor Disease (CLARICO)

NCT06789445
View directory record Official record
Conditions
Primary Photoreceptor Disease, Retinitis Pigmentosa (RP), Usher Syndrome, Inherited Retinal Disease (IRD), Rod-Cone Dystrophy, Rod-Cone Disease, Retinal Degeneration, Cone-Rod Disease (C-RD), Cone-Rod Dystrophy
Interventions
OpCT-001
Biological
Lead sponsor
BlueRock Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
5
States / cities
Los Angeles, California • Miami, Florida • Philadelphia, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 20, 2026, 6:20 PM EDT
Completed Phase 3 Interventional Results available

Study to Assess Efficacy and Safety of Cx601, Adult Allogeneic Expanded Adipose-derived Stem Cells (eASC) for the Treatment of Complex Perianal Fistula(s) in Participants With Crohn's Disease (CD)

NCT03279081
View directory record Official record
Conditions
Crohn's Disease
Interventions
Cx601, Placebo
Drug · Other
Lead sponsor
Tigenix S.A.U.
Industry
Eligibility
18 Years and older
Enrollment
568 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
68
States / cities
Scottsdale, Arizona • La Jolla, California • Los Angeles, California + 51 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 20, 2026, 6:20 PM EDT
Completed Phase 1 Interventional

Treatment of SCID Due to ADA Deficiency With Autologous Transplantation of Cord Blood or Hematopoietic CD 34+ Cells After Addition of a Normal Human ADA cDNA by the EFS-ADA Lentiviral Vector

NCT02022696
View directory record Official record
Conditions
Adenosine Deaminase Deficiency, ADA-SCID
Interventions
Lentiviral Gene Transfer
Genetic
Lead sponsor
National Human Genome Research Institute (NHGRI)
NIH
Eligibility
1 Year to 65 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 27, 2017 · Synced Oct 20, 2026, 6:20 PM EDT
Completed Phase 1 Interventional

CD-NP in Subjects With Stable Chronic Heart Failure

NCT00620308
View directory record Official record
Conditions
Stable Chronic Heart Failure
Interventions
CD-NP, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
21 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 10, 2012 · Synced Oct 20, 2026, 6:20 PM EDT
Terminated Phase 3 Interventional Results available

INFUSE®Bone Graft in Transforaminal Lumbar Interbody Fusion for Degenerative Disease of Lumbosacral Spine

NCT01415908
View directory record Official record
Conditions
Lumbar Spine Degeneration
Interventions
INFUSE Bone Graft, Iliac Crest Bone Graft
Device · Other
Lead sponsor
Medtronic Spinal and Biologics
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
5
States / cities
Mesa, Arizona • Los Angeles, California • Gulf Breeze, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2016 · Synced Oct 20, 2026, 6:20 PM EDT
Completed Phase 3 Interventional Results available

Compare Efficacy, Safety, and Immunogenicity of Proposed Rituximab Biosimilar (DRL_RI) With MabThera® in LTB Follicular Lymphoma

NCT03976102
View directory record Official record
Conditions
Follicular Lymphoma
Interventions
DRL_RI (Proposed rituximab biosimilar), MabThera®
Biological · Other
Lead sponsor
Dr. Reddy's Laboratories Limited
Industry
Eligibility
18 Years and older
Enrollment
317 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
4
States / cities
Whittier, California • Bethesda, Maryland • Knoxville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2024 · Synced Oct 20, 2026, 6:20 PM EDT
Completed Phase 1 Interventional

Safety Study of Chimeric Natriuretic Peptide(CD-NP) in Stable LVAD Patients

NCT01750905
View directory record Official record
Conditions
Left Ventricular Insufficiency
Interventions
CD-NP, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 90 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 30, 2016 · Synced Oct 20, 2026, 6:20 PM EDT